Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | FABP2 | P12104 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48556 | 0.88 | NR1H2 (0.34) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL13172618 | 0.83 | AKR1C3 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS1 | |
| SCHEMBL436559 | 0.78 | SLC6A2 (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL11993144 | 0.76 | CCR2 (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL12981613 | 0.76 | AKR1C3 (0.55) | PTGS1AKR1C3AKR1C2MEN1PTGS2 | |
| SCHEMBL7863630 | 0.76 | CCR2 (0.36) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14938633 | 0.75 | APP (0.52) | KCNH2PTGS1AKR1C3AKR1C2MEN1 | |
| SCHEMBL12982996 | 0.73 | MT-CO2 (0.44) | PTGS1PTGS2CYP2C19 | |
| SCHEMBL21164275 | 0.72 | CCR2 (0.38) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL6723560 | 0.71 | ALDH1A1 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-7998990-B2 | 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007134827-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 9/4885 |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | PIK3CD 12/4885PIK3CA 1/4885PIK3CB 9/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | PIK3CD 10/4885PIK3CA 1/4885PIK3CB 8/4885 |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | PIK3CD 42/4885PIK3CA 4/4885PIK3CB 34/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.